Technology | 2021.05.04
Palatin Announces U.S. Patent Term Extension for Vyleesi® (bremelanotide injection)
CRANBURY, N.J., May 4, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced that the United States...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]otide-injection-301282905.html
